Key Points
- Broadwood Partners bought 250,923 shares of Oncocyte on April 27 at $3.64 per share (≈$913,360), bringing its direct stake to 12,684,884 shares—a ~2.02% increase valued at about $46.17 million.
- The April 27 purchase is part of a recent accumulation spree by Broadwood, including a Feb. 10 acquisition of 521,739 shares at $5.75 (~$3.0 million) and multiple other buys in April, signaling continued insider buying pressure.
- Oncocyte has a market cap of about $123.5 million, reported negative EPS (‑$0.27) in its last quarter, a 12‑month trading range of $2.33–$8.51, and carries a mixed analyst consensus of “Hold” with an average target price of $12.00.
Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 250,923 shares of Oncocyte stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average cost of $3.64 per share, with a total value of $913,359.72. Following the acquisition, the insider directly owned 12,684,884 shares of the company's stock, valued at approximately $46,172,977.76. This trade represents a 2.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Broadwood Partners, L.P. also recently made the following trade(s):
- On Friday, April 24th, Broadwood Partners, L.P. bought 38,880 shares of Oncocyte stock. The shares were bought at an average cost of $3.53 per share, for a total transaction of $137,246.40.
- On Thursday, April 23rd, Broadwood Partners, L.P. purchased 280,381 shares of Oncocyte stock. The shares were bought at an average price of $3.50 per share, for a total transaction of $981,333.50.
- On Monday, April 20th, Broadwood Partners, L.P. purchased 40,690 shares of Oncocyte stock. The stock was bought at an average cost of $3.88 per share, with a total value of $157,877.20.
- On Friday, April 17th, Broadwood Partners, L.P. acquired 40,114 shares of Oncocyte stock. The stock was bought at an average price of $3.57 per share, with a total value of $143,206.98.
- On Thursday, April 16th, Broadwood Partners, L.P. acquired 102,057 shares of Oncocyte stock. The shares were bought at an average price of $3.45 per share, for a total transaction of $352,096.65.
- On Tuesday, February 10th, Broadwood Partners, L.P. bought 521,739 shares of Oncocyte stock. The shares were purchased at an average cost of $5.75 per share, for a total transaction of $2,999,999.25.
Oncocyte Stock Performance
Shares of NASDAQ:IMDX opened at $3.84 on Tuesday. The company has a market capitalization of $123.53 million, a PE ratio of -2.37 and a beta of 1.52. Oncocyte Corp has a 12 month low of $2.33 and a 12 month high of $8.51. The business's 50 day moving average price is $4.34.
Oncocyte (NASDAQ:IMDX - Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.27) earnings per share (EPS) for the quarter. The business had revenue of $1.14 million during the quarter.
Analyst Ratings Changes
IMDX has been the topic of a number of research analyst reports. Wall Street Zen lowered Oncocyte from a "hold" rating to a "sell" rating in a report on Saturday, March 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oncocyte in a report on Friday, March 27th. Finally, Lake Street Capital raised their price objective on shares of Oncocyte from $8.00 to $12.00 and gave the company a "buy" rating in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $12.00.
Check Out Our Latest Report on Oncocyte
Oncocyte Company Profile
(
Get Free Report)
Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.
Oncocyte's product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
